Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progesterone Clear all
Completed Not applicable Interventional Results available

Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation

NCT00563576
View directory record Official record
Conditions
Metrorrhagia
Interventions
Femring®, DepoProvera ®
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 18, 2026, 5:22 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Vaginal and Intramuscular Progesterone in Vitrified-warmed Blastocyst Transfer Cycles

NCT02772120
View directory record Official record
Conditions
Infertility
Interventions
Vaginal progesterone gel (Crinone® 8%), Intramuscular Progesterone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)

NCT00828191
View directory record Official record
Conditions
In Vitro Fertilization
Interventions
Progesterone
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Redondo Beach, California • San Jose, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

NCT02357368
View directory record Official record
Conditions
HIV, Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD), ParaGard® T 380A Intrauterine Copper Contraceptive
Drug · Device
Lead sponsor
Lisa Haddad
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 18, 2026, 5:22 PM EDT
Recruiting Phase 4 Interventional

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

NCT05282277
View directory record Official record
Conditions
Depression, Psychosis, Anhedonia
Interventions
Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 18, 2026, 5:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Progesterone in Pregnancy-2

NCT04753957
View directory record Official record
Conditions
Pregnancy Related
Interventions
micronized Progesterone
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
16 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion

NCT01809639
View directory record Official record
Conditions
Concussion
Interventions
Progesterone, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 44 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 18, 2026, 5:22 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

NCT00929006
View directory record Official record
Conditions
Puberty, Hyperandrogenism
Interventions
Micronized progesterone suspension, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

NCT00882258
View directory record Official record
Conditions
Uterine Fibroids
Interventions
12.5 mg Proellex, 25 mg Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 18, 2026, 5:22 PM EDT
Terminated Early Phase 1 Interventional

Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer

NCT01138553
View directory record Official record
Conditions
Invasive Breast Cancer, Ductal Carcinoma in Situ
Interventions
Mifepristone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neurosteroid Intervention for Menopausal and Perimenopausal Depression

NCT03505905
View directory record Official record
Conditions
Major Depressive Disorder, Menopause, Perimenopause
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 67 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 18, 2026, 5:22 PM EDT
Terminated Phase 1 Interventional Results available

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

NCT04296942
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
Interventions
Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Results available

A Treatment Study for Premenstrual Syndrome (PMS)

NCT00001259
View directory record Official record
Conditions
Premenstrual Syndrome, Menstruation Disturbances
Interventions
Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan

NCT04149002
View directory record Official record
Conditions
Preterm Birth
Interventions
Intervention Arm Weekly IP3 text messages, Active Control Arm General pregnancy text messages
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Progesterone for the Treatment of COVID-19 in Hospitalized Men

NCT04365127
View directory record Official record
Conditions
COVID-19, Sars-CoV2
Interventions
Progesterone 100 MG
Drug
Lead sponsor
Sara Ghandehari
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 18, 2026, 5:22 PM EDT
Recruiting No phase listed Observational

Endometriosis Pain

NCT06101303
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Psychophysical assessment, Psychophysical assessments of experimental pain, Blood, urine and saliva samples, Biopsy and surgery-related data.
Other · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Progesterone Effect on Individuals Diagnoses With AD and PTSD.

NCT02187224
View directory record Official record
Conditions
Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Interventions
Progesterone, Placebo (for Progesterone)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing IM vs. Vaginal Progesterone for Pre-term Birth

NCT00579553
View directory record Official record
Conditions
Infant, Premature, Premature Birth
Interventions
Intramuscular Progesterone, Vaginal Progesterone
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 18, 2026, 5:22 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone

NCT01428089
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism, Normal Puberty
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 18, 2026, 5:22 PM EDT
Recruiting Phase 2 Interventional

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06979596
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant, Exemestane, Megestrol acetate/Medroxyprogesterone acetate, Tamoxifen, Letrozole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Anchorage, Alaska • Miami Beach, Florida • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

NCT00134680
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Letrozole, Trastuzumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 18, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

NCT00573755
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, exemestane, letrozole, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 18, 2026, 5:22 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine

NCT05738213
View directory record Official record
Conditions
Migraine
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Pressure pain thresholds (PPT), Conditioned pain modulation (CPM) response, PedMIDAS (Pediatric Migraine Disability Assessment), Hormonal assessment, Pubertal status
Device · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
11 Years to 15 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 18, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

MENOPUR® Versus FOLLISTIM®

NCT00802360
View directory record Official record
Conditions
Infertility
Interventions
Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Pasadena, California • San Diego, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 18, 2026, 5:22 PM EDT